Clinical Trials
57 trialsHyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
Biotech Pharmaceutical Co., Ltd.
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
LIQPLAT
University Hospital, Basel, Switzerland
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Barbara Ann Karmanos Cancer Institute
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
Shandong Cancer Hospital and Institute
A Study of ES014 in Subjects With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment
The Affiliated Hospital Of Guizhou Medical University
PRECIOUS-01
Radboud University Medical Center
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
Ruijin Hospital
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
China-Japan Friendship Hospital
BT02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ISCA-CHECK
University Hospital, Basel, Switzerland
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Sichuan University
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Changzhou No.2 People's Hospital
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Promise
Hunan Province Tumor Hospital
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Chinese PLA General Hospital
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
The First Affiliated Hospital of Guangzhou Medical University
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Peking University
ATI-2231 in Advanced Solid Tumor Malignancies
Washington University School of Medicine
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
Shanghai East Hospital
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
Shanghai East Hospital
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor
Peking University
A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
A Study of IMC008 for Advanced Solid Tumors
Changhai Hospital
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
The Affiliated Hospital of Xuzhou Medical University
A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors
The First Affiliated Hospital of Bengbu Medical University
Special Combination of OBP-301 and Pembrolizumab
National Cancer Center Hospital East
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor
The Affiliated Hospital of Qingdao University
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
The First People's Hospital of Lianyungang
PROFILER 02
Centre Leon Berard
A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors
The Affiliated Hospital of Xuzhou Medical University
A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors
The First Affiliated Hospital of Bengbu Medical University